Jonathan Kalman

Jonathan Kalman is the founder and CEO of Dion Holding Ltd, which invests in early-stage Israeli technology companies with an emphasis on biopharma and medical devices. Jonathan was a member of the Board of Directors of Neuroderm (NDRM) from November 2014 until its acquisition by Mitsubishi Tanabe Pharma Corporation in October 2017 for $1.1 Billion.

Jonathan is currently a director of Revelator Ltd., a leading supplier of data services for today’s digital rights business. He is also on the board of directors of The Jerusalem Print Workshop, a non-profit art center dedicated to the advancement of the graphic arts in Israel.